OptiPharm is trading at 4725.00 as of the 21st of November 2024, a 0.84% down since the beginning of the trading day. The stock's open price was 4765.0. OptiPharm has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for OptiPharm Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Although OptiPharm's alpha and beta are two of the key measurements used to evaluate OptiPharm's performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OptiPharm stock to make a market-neutral strategy. Peer analysis of OptiPharm could also be used in its relative valuation, which is a method of valuing OptiPharm by comparing valuation metrics with similar companies.